Internet Live Course Webinar: Emerging Therapies for PBC, NASH, ESLD and HCC - October 3 and 10, 2020

This streaming activity will provide updates on the diagnosis and treatment of chronic liver disease with a focus on patient care and symptom management. A national faculty of liver disease experts has come together to deliver state-of-the-art material and true-to-life clinical cases. This program will concentrate on current and emerging diseases of the liver and address the latest diagnosis, treatment, and care management approaches for each. We hope you enjoy the activity and translate its lessons to improve patient outcomes in your practice.
When Oct 03, 2020 08:00 AM to
Oct 10, 2020 11:30 AM
Where Various Dates and Locations - See Below
Contact Name
Add event to calendarvCal
iCal


Internet Live Course Webinar Part I October 3, 2020
Internet Live Course Webinar Part II October 10, 2020
8:00am – 11:30am (Pacific) each day



Target Audience
The target audience for this activity is Gastroenterologists, Internists, Hepatologists, family physicians as well as related advanced-practice providers and nurse specialists. 

Joint Provider Statement
 This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville School of Medicine and SC Liver Research Consortia. The University of Louisville School of Medicine is accredited by the ACCME to provide continuing education for physicians.

 Designation Statement
 The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.3 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Completion criteria to obtain CE's: Attend entire session and complete the evaluation.

Instructions 

This CME activity will be presented in two parts on consecutive Saturdays in October.  Once you have registered for the webinar, you will be sent log-on information to access the presentations via Zoom.
Once the webinar is over on October 10, you may complete the course evaluation, after which you will be able to generate your CME/CE certificate.

Webinar Faculty

Paul Pockros, MD 
- Course Co-Director  Director, Liver Disease Center, Scripps Clinic, La Jolla, CA

Catherine Frenette, MD - Course Co-Director  Medical Director for Liver Transplantation, Scripps Center for Organ and Cell Transplantation, La Jolla, CA

Robert Fontana, MD – Professor of Medicine, University of Michigan School of Medicine  Ann Arbor, MI

Mazen Noureddin, MD – Founding Director, Fatty Liver Program, Cedars Sinai Medical Center, Beverly Hills, CA

Kirti Shetty, MD – Professor of Medicine, University of Maryland School of Medicine, Baltimore, MD

Learning Objectives
After attending this course, participants should be able to:

  • Summarize the causes of chronic liver disease and hepatic encephalopathy and promising treatments.
  • Comprehend the complexities of organ transplant procedures and waitlists.
  • Perform the appropriate diagnostic tests required to ensure early diagnosis of hepatocellular carcinoma (HCC).
  • Integrate newer treatment options for HCC as well as approaches to reduce tumor size and number.
  • Review the current therapies for PBC and clinical approaches for PSC.
  • Discuss the importance of liver biopsy for assessment of PSC and NASH as well as emerging, non-invasive diagnostic tools and procedures.
  • Learn about diagnostic tests for NASH that may become in daily use soon.
  • Translate approaches and findings from the 2019 EASL and AASLD key presentations to your setting.
  • Discover why Immunotherapy is the new Method of Action for Hepatocellular Carcinoma.
  • Discuss treatment options for thrombocytopenia; including therapeutic alternatives to platelet transfusion.
  • Employ the progression pathways of Fatty Liver Disease to NASH to Liver Cancer to improve patient management.
  • Utilize current clinical cases to improve diagnostic and treatment skills.
  • Update knowledge on new treatments for liver diseases using evidence-based approaches.

Registration
Registration Fees: 
There is no charge for this program. However, advance registration is required. Participants will receive webinar instructions before the conference so they are able to prepare and perform a system check.

CLICK HERE to Register for this Conference


Hardware & Software Requirements
High speed internet connection
A computer with sound is required.  One with an onboard camera is recommended
Browser: Google Chrome is recommended

Commercial Support

This activity is Supported by educational grants from Allergan Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Dova Pharmaceuticals, Eisai, Inc., Exelixis, Intercept Pharmaceuticals, Merck & Co. and Salix – A Division of Bausch Health.